DR Market News Briefs

Biopharma, Tech Stocks Lead European Equities Slightly Lower


Last updated: 01/25/2023 11:10:01

11:10 AM EST, 01/25/2023 (MT Newswires) -- Biopharmaceutical firms and tech stocks led European equities modestly lower in Wednesday trading, as American depositary receipts of European stocks were down 0.22% to 1,161.41 on the S&P Europe Select ADR Index.

In continental Europe, the gainers were led by biopharmaceutical companies MorphoSys (MOR) and Grifols (GRFS), which rose 3.1% and 2.2%, respectively. They were followed by pharmaceutical company Sanofi (SNY) and telecommunications company Nokia (NOK), which were up 0.7% and 0.3%, respectively.

The decliners in continental Europe were led by biopharmaceutical company Cellectis (CLLS) and 3D printer company voxeljet (VJET), which fell 8.4% and 6.5%, respectively. They were followed by internet browser company Opera (OPRA) and dating app operator Spark Networks (LOV), which dropped 6.1% and 4.2%, respectively.

In the UK and Ireland, the gainers were led by biopharmaceutical company Akari Therapeutics (AKTX) and pharmaceutical company Avadel Pharmaceuticals (AVDL), which advanced 6.7% and 5.6%, respectively. They were followed by financial services companies Lloyds Banking Group (LYG) and Barclays (BCS), which increased 2.2% and 1.2%, respectively.

The decliners in the UK and Ireland were led by biotech firm Autolus Therapeutics (AUTL) and software firm Endava (DAVA), which lost 5.3% and 4%, respectively. They were followed by biopharmaceutical companies Bicycle Therapeutics (BCYC) and Adaptimmune Therapeutics (ADAP), which were down 2.2% and 1.6%, respectively.

Copyright © 2023 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2021 Wall Street Horizon, Inc.